Summary
The AI statements address pricing and payer/specialty pharmacy effects, but the provided FDA label excerpts do not contain any information about pricing, reimbursement, out-of-pocket cost, or specialty pharmacy channel effects. Therefore, the statements cannot be verified against the supplied prescribing information.
Category Scores
Accurate Statements
Unsupported Statements
Fabhalta (iptacopan) pricing is not a single fixed number.
No pricing information is present in the supplied FDA label excerpts.
Fabhalta pricing depends on the country.
No pricing-by-country information is present in the supplied FDA label excerpts.
Fabhalta pricing depends on the exact presentation/pack size.
No pack-size or presentation-dependent pricing information is present in the supplied FDA label excerpts.
Fabhalta pricing depends on the insurer or payer.
No payer/insurer pricing or reimbursement information is present in the supplied FDA label excerpts.
Fabhalta pricing depends on whether a patient pays the list price or a negotiated price through a pharmacy benefit.
No list price vs negotiated price information is present in the supplied FDA label excerpts.
“Fabhalta price” searches can yield different figures depending on the source (cash/list pricing vs. insurance pricing).
No information about search results, sources, or cash vs insurance pricing is present in the supplied FDA label excerpts.
Most real-world “Fabhalta price” lookups are about out-of-pocket cost.
No information about typical “real-world lookups” or out-of-pocket cost usage is present in the supplied FDA label excerpts.
Out-of-pocket cost for Fabhalta depends on insurance coverage (formulary tier, prior authorization).
No out-of-pocket cost drivers (formulary tier/prior authorization) are present in the supplied FDA label excerpts.
Out-of-pocket cost for Fabhalta depends on the pharmacy used and whether the plan uses a specific specialty pharmacy.
No out-of-pocket cost by pharmacy/specialty pharmacy channel is present in the supplied FDA label excerpts.
Out-of-pocket cost for Fabhalta depends on co-pay/coinsurance rules in the patient’s plan.
No co-pay/coinsurance information is present in the supplied FDA label excerpts.
Out-of-pocket cost for Fabhalta depends on patient assistance or discount programs (if available).
No information about patient assistance/discount programs is present in the supplied FDA label excerpts.
Drugs like Fabhalta are often handled through specialty pharmacy channels after launch.
No statements in the supplied FDA label excerpts discuss specialty pharmacy channels (aside from a REMS-related restricted program requirement).
Specialty pharmacy channels can affect the effective price a patient sees at checkout even when the manufacturer list price is unchanged.
No pricing mechanics at checkout or effective price impacts are present in the supplied FDA label excerpts.
Contradictions
Important Omissions
Any label-supported information about FABHALTA dosing/administration, contraindications, serious infection risk management (vaccination/prophylaxis), monitoring, adverse reactions, or REMS requirements.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
The AI statements concern pricing/reimbursement logistics and do not include medication safety instructions, contraindications, or misuse-related claims that could directly conflict with the supplied label excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Claims are about pricing/reimbursement and are not addressed in the supplied FDA label excerpts, so label alignment cannot be established.
Suggested Improvement
Limit statements to content supported by the provided label excerpts (e.g., infection risk, vaccination/prophylaxis timing, contraindication on initiation in unresolved serious encapsulated bacterial infection, and REMS/restricted program counseling and requirements), or provide label text that specifically addresses pricing/reimbursement.